These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30045034)

  • 1. Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.
    Hsiehchen D; Arasaratnam R; Raj K; Froehlich T; Anderson L
    Oncology; 2018; 95(5):319-322. PubMed ID: 30045034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
    Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
    Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
    Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
    Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
    [No Abstract]   [Full Text] [Related]  

  • 4. Progressive Multifocal Leukoencephalopathy Among Ibrutinib Treatment In Chronic Lymphocytic Leukemia.
    Çetintepe T; Gediz F; Akyar I; Çetintepe L; Koç AM
    J Oncol Pharm Pract; 2022 Jul; 28(5):1249-1253. PubMed ID: 35037793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Saenz-de-Viteri M; Cudrnak T
    Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib treatment of mantle cell lymphoma complicated by progressive multifocal leukoencephalopathy
.
    Mosna K; Ladicka M; Drgona L; Vranovska M; Hojsikova I; Tomasova R; Danihel L; Kyselovic J; Babal P
    Int J Clin Pharmacol Ther; 2020 Jun; 58(6):343-350. PubMed ID: 32213285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Tahir F; Sy J; Reddel S; Trotman J
    Leuk Lymphoma; 2022 Jun; 63(6):1464-1468. PubMed ID: 35037559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-associated progressive multifocal leukoencephalopathy.
    Sokol J; Lisá L; Zeleňáková J; Balhárek T; Plameňová I; Staško J; Kubisz P
    Vnitr Lek; 2017; 63(1):60-64. PubMed ID: 28225293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus.
    Ramadhani P; Bramantono B; Sedana MP
    Acta Med Indones; 2018 Apr; 50(2):151-158. PubMed ID: 29950535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Goldschmidt N; Rund D
    Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Sato R; Jacob J; Gaballa S
    Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
    [No Abstract]   [Full Text] [Related]  

  • 13. Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
    Faisal MS; Shaikh H; Khattab A; Albrethsen M; Fazal S
    J Oncol Pharm Pract; 2019 Sep; 25(6):1486-1490. PubMed ID: 30045683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obinutuzumab use complicated by progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukemia: a case report.
    Turine G; London F
    Acta Neurol Belg; 2021 Jun; 121(3):781-783. PubMed ID: 33063195
    [No Abstract]   [Full Text] [Related]  

  • 16. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
    Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
    JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
    Molica S; Levato L; Mirabelli R
    Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
    [No Abstract]   [Full Text] [Related]  

  • 19. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
    Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS
    Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.